Brief: SynAct Pharma Identifies Sub-Population Of Patients Responding To Resomelagon

SynAct Pharma AB

13/09/2023 07:07

Sept 13 (Reuters) - SynAct Pharma AB  SYNACT.ST :
    * ANNOUNCED ON TUESDAY ADDITIONAL DATA FROM EXPAND P2B
CLINICAL
TRIAL AND IDENTIFIED POPULATION WITH RESPONSIVENESS TO
RESOMELAGON
    * A SUB-POPULATION OF PATIENTS WITH A BASELINE MARKER OF
SYSTEMIC
INFLAMMATION (CRP > 3MG/L) DEMONSTRATED A CONSISTENT RESPONSE TO
THERAPY OVER PLACEBO ACROSS ALL ASSESSED OUTCOME MEASURES
    * SYNACT PREVIOUSLY ANNOUNCED THAT THE STUDY DID NOT MEET
THE
PRIMARY ENDPOINT OF A SIGNIFICANTLY HIGHER ACR20 RESPONSE AT 12
WEEKS AS COMPARED TO PLACEBO
    * NOW IDENTIFIES A PATIENT POPULATION WITH ACTIVE SYSTEMIC
INFLAMMATION, WHERE RESOMELAGON DEMONSTRATED ACTIVITY OVER
PLACEBO ON THE ACR20 PRIMARY ENDPOINT AS WELL AS ALL OTHER
ASSESSED SECONDARY OUTCOME MEASURES
    * SYNACT MANAGEMENT WILL HOLD AN INVESTOR WEBCAST TO DISCUSS
THIS
UPDATE

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nMFN44HzgD
 Further company coverage:  SYNACT.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))